Hormone Testing for Bioidentical Hormone Therapy: Which Labs Matter and What They Mean

Looking for the bioidentical versus synthetic comparison? That question — what "bioidentical" means at the molecular level, how estradiol and micronized progesterone differ from conjugated equine estrogens and medroxyprogesterone acetate, what the Women's Health Initiative actually reported, and why route matters — is answered in full here: BHRT vs HRT: What the Difference Actually Is, and What the Evidence Shows. This page picks up where that one ends, at the lab slip.

The short version. Labs do three jobs: they rule out the conditions that imitate hormone decline, they establish a baseline to measure change against, and once you are on treatment they confirm absorption and flag unintentionally high exposure. They do not diagnose menopause in most women, they do not set your estrogen dose, and they do not tell you how you feel.

Why We Test at All

There is a version of hormone care where a symptom questionnaire leads straight to a prescription, and a version where a lab panel is treated as a scoreboard to be maximized. Neither is right. Testing earns its place for three specific reasons.

To rule things out. Fatigue, brain fog, low mood, weight change and low libido are the shared final common pathway of a dozen conditions. Thyroid disease, anemia, poorly controlled glucose, elevated prolactin and depression all present this way. Prescribing hormones into an undiagnosed thyroid problem does not fix the thyroid problem.

To create a baseline. A single hormone level in isolation is nearly uninterpretable. The same number six weeks after starting treatment, next to your symptom notes, is genuinely useful. Most of a baseline panel's value is retrospective.

To keep exposure where it belongs. This is the safety function, and it is the one that matters most on an ongoing basis.

What a Baseline Panel Covers

Sex hormones

• Estradiol (E2). The primary estrogen produced by the ovaries. In perimenopause it swings rather than falls steadily, so one value is a snapshot of a moving target, not a verdict.
• Progesterone. Depends on ovulation, so it is interpreted against where you are in your cycle if you are still cycling. Declining progesterone is often the earliest change in perimenopause.
• Total and free testosterone. Women produce testosterone in the ovaries and adrenal glands and levels decline gradually from the 20s and 30s onward. Free testosterone is the fraction not bound to carrier proteins.
• SHBG (sex hormone-binding globulin). The carrier protein that determines how much of your testosterone and estradiol is actually available to tissue. Oral estrogen and some oral contraceptives raise SHBG, which lowers free hormone even when total levels look unremarkable. This is why a "normal" total testosterone can sit alongside genuine symptoms.
• DHEA-S. An adrenal precursor hormone, more stable across the day than DHEA itself.
• FSH and LH. Useful in specific situations — suspected early menopause, or a picture that does not fit the age — but not required to make the diagnosis in most women.

The look-alikes

• Thyroid: TSH, free T4, free T3, and where indicated reverse T3 and thyroid antibodies. A TSH alone is the single most common gap we see in panels done elsewhere.
• Prolactin. An elevated prolactin can flatten desire and disrupt cycles, and it changes the plan entirely if present.
• CBC and ferritin. Iron deficiency, with or without anemia, produces fatigue that no hormone will fix. Heavy perimenopausal bleeding makes this common and easy to miss.
• Comprehensive metabolic panel, lipids, fasting glucose and A1c. Baseline cardiometabolic picture, and part of assessing candidacy.
• Vitamin D. Relevant to bone health alongside estrogen.
• AM cortisol. Assessed where the history suggests it, in the context of sleep and stress rather than as a standalone verdict.

What sits alongside the bloodwork

Blood pressure, weight and body composition, a structured symptom inventory, current mammography status, and a full personal and family history — clotting events, stroke, migraine with aura, breast and other estrogen-sensitive cancers, cardiovascular disease. These carry as much weight in the plan as any number on the panel.

Diagnosis Is Clinical, Not a Number

This is the part that most often surprises people. Menopause staging is built primarily on bleeding patterns, not on hormone levels. The Stages of Reproductive Aging Workshop + 10 consensus, the standard framework for describing where a woman is in the transition, simplified the bleeding criteria for the early and late menopausal transition and recommended applying the staging regardless of a woman's age, ethnicity, body size or lifestyle (Harlow et al., J Clin Endocrinol Metab, 2012, DOI). Your cycle history is the primary instrument. Labs support it.

The same logic applies to low desire. The International Society for the Study of Women's Sexual Health clinical practice guideline states directly that a total testosterone level should not be used to diagnose hypoactive sexual desire disorder, but as a baseline for monitoring (Parish et al., J Sex Med, 2021, DOI). A low number does not make the diagnosis and a normal one does not exclude it.

Serum, Not Saliva

Saliva testing is widely marketed alongside custom-compounded hormone preparations, often to justify a bespoke ratio. The problem is a specific technical one. A review in Climacteric addressing misconceptions about bioidentical hormone therapy notes that compounding pharmacies frequently use saliva testing to measure hormones, and that there is a misconception that salivary hormone levels are equivalent to the non-protein-bound — free — hormone fraction in blood (Stanczyk et al., Climacteric, 2021, DOI). They are not the same measurement, and a plan built on treating them as interchangeable is built on sand.

We use serum, run through LabCorp or Quest Diagnostics, so results are comparable over time and against published reference data.

Monitoring on Treatment: What Changes, and When

The 4 to 6 week recheck

The first follow-up panel comes 4 to 6 weeks after starting, and after pellet insertion specifically. Its job is narrow and important: confirm you are absorbing what you were prescribed, and confirm exposure has not overshot. Symptom notes from those weeks are read alongside it.

Estrogen: titrated to symptoms, not to a target

Systemic estrogen dosing follows your symptoms and your tolerance. A level confirms absorption and screens for unintentionally high exposure; it is not a score to be raised. This matters practically, because chasing a number is how people end up on more hormone than they need. Systemic estrogen reduces the frequency of hot flashes and night sweats by roughly 75 percent, and oral and transdermal routes are similarly effective for that purpose (Crandall et al., JAMA, 2023, DOI) — so if symptoms are controlled, the dose is doing its job whatever the number says.

Testosterone: the one we do watch against a range

Testosterone is the exception. Here the guideline is explicit: patients should be assessed for signs of androgen excess, and total testosterone monitored to maintain concentrations within the physiologic premenopausal range (Parish et al., 2021, DOI). The target is a normal young-woman level, not a male level, and the Global Consensus Position Statement endorsed by eleven international societies frames it the same way (Davis et al., J Clin Endocrinol Metab, 2019, DOI).

Progestogen and the endometrium

If you have a uterus and are taking systemic estrogen, a progestogen is part of the plan and endometrial protection is a clinical question, not a lab question. Any unscheduled or postmenopausal bleeding is evaluated regardless of what your hormone levels show. No lab result overrides that.

The ongoing schedule

After the early recheck, the cadence is set by what you are taking and how you responded — commonly a panel at around three months, then periodically thereafter, with metabolic markers folded in less often. The 2022 Menopause Society position statement recommends that treatment be individualized with periodic reevaluation of whether to continue (Menopause, 2022, DOI). Monitoring is what makes that reevaluation possible rather than theoretical.

How to Time Your Draw

• If you are still cycling, progesterone is usually drawn in the luteal phase, roughly days 19 to 22 of a 28-day cycle. Tell us your cycle dates rather than estimating.
• Morning draws for testosterone, DHEA-S and cortisol, since these follow a daily rhythm.
• Fasting for glucose, A1c and lipids.
• On treatment, be consistent. Same interval after your cream, patch or injection each time. Comparing a trough to a peak produces a change that is not real.
• Bring your medication list, including supplements. Biotin in particular can interfere with some immunoassays; we will tell you when to hold it.

What Labs Cannot Tell You

Three honest limits.

They cannot tell you how you feel. Two women with identical estradiol levels can have completely different symptom burdens. Treatment follows the symptom.

They cannot resolve perimenopause. During the transition levels move week to week. A single estradiol drawn on a Tuesday describes Tuesday. This is why the cycle history carries the diagnostic weight (Harlow et al., 2012, DOI).

They cannot substitute for a risk conversation. Whether hormone therapy suits you turns on how far you are from your final period, your clotting and vascular history, whether you still have a uterus, and your breast history. None of that appears on a panel. The evidence behind those judgements is laid out in our BHRT vs HRT guide.

How This Works at Arbour Longevity

Your first visit is $35, applied toward your treatment plan, and includes a full evaluation and a specific recommendation on which labs are worth drawing for you — not a maximal panel by default. Labs are ordered through LabCorp or Quest and billed separately by the lab; depending on your plan, part of a panel may be covered even though the clinic is cash-pay. HSA and FSA funds are accepted.

If you want the full programme cost and visit schedule, that is set out in BHRT for women over 40: what it costs and your first three months. For the treatment itself, see hormone replacement therapy in Ann Arbor, our work as a menopause specialist in Ann Arbor, and longer-term hormone optimization. For more on bioidentical versus conventional hormone therapy in Ann Arbor, see our Ann Arbor guide to bioidentical versus conventional hormone therapy.

Frequently Asked Questions

Do I need a blood test to know if I am in menopause?

Usually not. Menopause staging rests primarily on bleeding patterns, and the STRAW + 10 framework is built around them (Harlow et al., 2012, DOI). Labs are more useful for ruling out look-alike conditions and for establishing a baseline than for making the diagnosis itself.

Why did my provider only check TSH?

A TSH alone is the standard screening approach in general practice and it catches a lot. It can also miss conversion and antibody issues that a fuller picture — free T4, free T3, and where indicated reverse T3 and thyroid antibodies — would show. Given how completely thyroid symptoms overlap with hormone decline symptoms, we look at the fuller picture before attributing anything to hormones.

Is saliva testing useful?

We use serum. Salivary hormone levels are frequently presented as equivalent to the free hormone fraction in blood, and that equivalence is a misconception (Stanczyk et al., 2021, DOI). Serum results are comparable over time and against published data.

My estradiol is "normal" but I feel terrible. What now?

Then the number is not the useful piece of information. Look at SHBG and free hormone rather than totals alone, at thyroid, ferritin and prolactin, at sleep and at medications. Treatment decisions follow symptoms and tolerance, not a target value.

How often will I need labs once I am stable?

Commonly a panel at the 4 to 6 week mark, again at around three months, then periodically. The interval depends on what you are taking, how you responded, and whether anything changes. Reevaluation is meant to be periodic rather than annual by habit (Menopause, 2022, DOI).

Can I bring labs from another provider?

Yes, and please do. Prior results are genuinely valuable because they give us a trend rather than a point. We will tell you what, if anything, still needs repeating.

Hormone Consultations in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner and founder of Arbour Longevity. We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters, no structure. Suite 15 is down a flight of stairs; if stairs are difficult for you, please call (734) 436-3357 before your visit.

Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

References

According to PubMed, the clinical evidence cited on this page includes:

1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. J Clin Endocrinol Metab. 2012;97(4):1159-1168. PMID: 22344196. DOI: 10.1210/jc.2011-3362
2. Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. PMID: 33814355. DOI: 10.1016/j.jsxm.2020.10.009
3. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID: 31498871. DOI: 10.1210/jc.2019-01603
4. Stanczyk FZ, Matharu H, Winer SA. Bioidentical hormones. Climacteric. 2021;24(1):38-45. PMID: 33403887. DOI: 10.1080/13697137.2020.1862079
5. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420. PMID: 36749328. DOI: 10.1001/jama.2022.24140
6. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PMID: 35797481. DOI: 10.1097/GME.0000000000002028

Clinical information here is drawn from articles retrieved from PubMed and provided for education. It is not medical advice, a diagnosis, or a promise of any result.